Andrew Hartten o f DuPont presented DuPont's work related to RFI program.

DuPont Intemal Memo, "C-8 Study" (8/5/96) (EID107066-71); 4 DuPont Epidemiology Surveillance Report, "Mortality And Cancer Incidence Surveillance At Washington Works" (6/30/96) (EID121880-94); 5.

DuPont's community and wolker action levels for C-8.

DuPont Internal Memo, "C-8 Study" (8/5/96) (EID107066-71); 4.

That same vear, DuPont reassigned 50 women at the plant to reduce PFOA exposure.

DuPont Co. 7 3Dbd 7i n 7LL S0 136 2-5808-a lirUM3dnana:ai 88:60 10.

Frame, a veterinary pathologist at DuPont (the study pathologist for the DuPont Study).

In over 50 yearsofuse by DuPont and others, DuPont is not awareofany adverse human health effects that have been shown to be. caused by PFOA.

DuPont Report, "C-8 Data Summary Report: Consent Order GWR-2001-019: DuPont Washington Works Facility and Local, Letart and Dry Run Landfills" (February 2003); 4.

, DuPont Bernard, J.

DuPont Haskell Laboratory FYL-6 0ii?

Ritehey" <RITCHERL@wwps-a1 .email.clupont.com>, Isidores J Zanlkos/AE/DuPontfgOuPont, Michael J Lukas/AE/DuPontQDuPont, Andrea Malinowski/DPL/DUP@DUP, Timothy S 8ingman/AE/DuPont@DuPont, Patricia A Westphal/CUDuPontigOuPont, J Stephen Opp/AE/DuPont@DuPont, Michael A Turco/AE/DuPontQOuPont, Elizabeth B Bishop/AE/DuPont@DuPont, Robert F PinohoVDEV/AE/DuPont@OuPont "ALISON A.

DuPont Haskell Laboratory FYL-6 0ii?

AR226-2509 # # Stephen R Peck 03/07/2002 08:21 PM To: Yasu Shibuta/SE/DuPont@DuPont cc: Ta-Wei Fu/SE/DuPont@DuPont, Mohammad Rezaei/SE/DuPont@DuPont Subject: Procedure for Analytical Determination of APFO Procedure for Analytical Determinatior EDD0042621

A control group of DuPont office workers in Wilmington, Delaware was also tested.